Traditionally, Phase 1 clinical trials are small-scale and straightforward. However, with the growing trend towards personalized medicine and gene therapies, today’s Phase 1 clinical trials are increasingly complex. 

A biopharmaceutical company had an early-phase oncology study with an adaptive trial design and open-label enrollment. The sponsor needed an IRT solution to help manage complex stratification, site activity, and patient management. However, they did not need the robust functionality or expense of an IRT system that supported Phase 2 or 3 studies.

YPrime delivered:

Our IRT platform with flexible supply management

Sponsor-controlled cohort management

Easy adjustment of dispensing levels

And faster protocol amendment implementation

At YPrime, we pioneer solutions that streamline the clinical trial journey, increasing certainty from study design to data lock. Download this case study and find out why top pharma leaders and emerging biotech companies continue to choose YPrime for eConsent, IRT, eCOA, and patient engagement solutions.